Molecular detection and therapeutic management of Babesia gibsoni and Ehrlichia canis co-infection in dogs along with characterisation of the pathogens.
Pati Mirashree M, Biswal Sangram S, Mishra Smruti Ranjan SR, Dehuri Manaswini M et al.
Tick-borne hemoparasitic infections constitute an important cause of clinical morbidity in dogs, particularly in endemic regions where vector exposure facilitates concurrent transmission of multiple pathogens. This study aimed to molecularly detect and characterise Babesia gibsoni and Ehrlichia canis co-infection in dogs, assess associated clinico-hemato-biochemical alterations, and evaluate the therapeutic efficacy of artesunate-atovaquone-doxycycline (AAD) regimen. A total of 184 clinically suspected dogs were screened by internally controlled multiplex PCR, and positive cases were further confirmed by species-specific real-time quantitative PCR (qPCR) and sequencing. The prevalence of B. gibsoni and E. canis co-infection was 7.6% (14/184). Eight infected dogs were treated with AAD protocol and the relative abundance of parasite target DNA was assessed on days 0, 10, 28, and 90 using relative quantification (RQ) qPCR targeting B. gibsoni 18S rRNA and E. canis VirB9 gene that has been normalized to canine β-actin by the 2-ΔΔCt method. Infected dogs exhibited normocytic-normochromic anaemia, thrombocytopenia, hypoproteinaemia, hyperglobulinaemia, hyperbilirubinemia, azotaemia, high serum alkaline phosphatase and aspartate transaminase level whereas, mean creatinine level were found within normal physiological range. Following AAD therapy, dogs showed rapid clinical recovery, with significant improvement in hemato-biochemical parameters by day 90. Significant reduction in parasite DNA load was noted, reflected by rising Ct values and progressively declining log RQ values for both pathogens. These findings indicated that the AAD regimen showed potential effectiveness against canine B. gibsoni and E. canis co-infection, however this preliminary clinical observation may be validated through further controlled trials.